

Special Issue

Towards Precision Medicine in Diabetes and Related Complications

Message from the Guest Editor

Diabetes increases the risk of premature mortality and morbidity as a result of multisystem complications during the lifelong disease course. Due to the epidemic proportion that diabetes is assuming, thus greatly contributing to an increase in economic, social and human costs worldwide. To tackle such a burden, the development of precision medicine approaches to predict the most high-risk patients to be targeted with the most aggressive, expensive and burdensome prevention strategies is mandatory. The use of “omics” information leading to the discovery of novel biomarkers and their integration in prediction models that incorporate data from accurate phenotyping would help clinicians to stratify patients’ individual risk in order to choose the best follow-up and treatment strategies so as to maximize their effectiveness and minimize their costs. It aims to highlight some of the latest studies in the field of “omics”, in the application of precision medicine for people with diabetes and coincidentally in addressing pathogenic pathways that are either unknown or poorly understood and that can eventually become the target of new treatments.

Guest Editor

Dr. Claudia Menzaghi

Research Unit of Diabetes and Endocrine Diseases, Scientific Institute "Casa Sollievo della Sofferenza", Viale Padre Pio, 71013 San Giovanni Rotondo, Italy

Deadline for manuscript submissions

closed (10 June 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/91487

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).